# Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer

> **NCT03829722** · PHASE2 · COMPLETED · sponsor: **University of Michigan Rogel Cancer Center** · enrollment: 26 (actual)

## Conditions studied

- Oropharynx Squamous Cell Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Carboplatin
- **DRUG:** Paclitaxel
- **RADIATION:** Radiation Therapy

## Key facts

- **NCT ID:** NCT03829722
- **Lead sponsor:** University of Michigan Rogel Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-09-05
- **Primary completion:** 2024-06-11
- **Final completion:** 2024-06-11
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2026-01-22

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03829722

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03829722, "Radiotherapy, Carboplatin/Paclitaxel and Nivolumab for High Risk HPV-related Head and Neck Cancer". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT03829722. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*